114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)

ESMO Open 2026 Open access

Read full text
Authors: G. Schvartsman, D. Yue, M. Provencio Pulla, H. Liu, L. Liu, G. Han, L. Zhang, K. Naicker, N. Zhao, X. Lin, M. Austin Taylor, S. Peters
+2 more L. Cao, C. Wang
DOI: 10.1016/j.esmoop.2026.106421
Cited by: 2

Abstract

In RATIONALE-315 (NCT04379635), perioperative (periop) TIS + neoadjuvant chemotherapy (neoadj CT) showed significant improvement vs placebo (PBO) + neoadj CT in median event-free survival (mEFS) and overall survival (mOS) in pts with resectable stage II-IIIA NSCLC. This post hoc analysis explored how pathologic regression by RVT% and lymph node (LN) status impacts survival in RATIONALE-315 pts with stage II vs IIIA disease.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment Cancer Stress Anesthesia and Immune Response

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106421–106421
Publication date
17 March 2026
Language
EN